Green Cross and OctoPlus signed joint development of new drug for mid-ear infection.

Published: 2006-11-24 06:59:00

Updated: 2006-11-24 06:59:00

Green Cross signed an agreement with OctoPlus NV, a Netherlands company, on Nov. 22 for an exclusive distribution in Korea and joint development of OP-145, a drug for the treatment of chronic middle ear infection (otitis media).

OP-145 is an ear drop directly applicable to ears for the treatm...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK